Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic activity
Journal of Clinical Investigation · 16.12.2024 · 134 (24)
DOI: 10.1172/jci177077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 31.10.2024. Verfasst von Qingnian Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Disulfides, Endoplasmic Reticulum Stress, Oxygenases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Key R & D Projects of Zhejiang Province.
Abstract (Originalsprache)
Myocardial infarction (MI) is characterized by massive cardiomyocyte (CM) death and cardiac dysfunction, and effective therapies to achieve cardioprotection are greatly needed. Here, we report that flavin-containing monooxygenase 2 (FMO2) levels were markedly increased in CMs in both ex vivo and in vivo models of ischemic injury. Genetic deletion of FMO2 resulted in reduced CM survival and enhanced cardiac dysfunction, whereas CM-specific FMO2 overexpression conferred a protective effect in infarcted rat hearts. Mechanistically, FMO2 inhibited the activation of ER stress–induced apoptotic proteins, including caspase 12 and C/EBP homologous protein (CHOP), by downregulating the unfolded protein response pathway. Furthermore, we identified FMO2 as a chaperone that catalyzes disulfide bond formation in unfolded and misfolded proteins through its GVSG motif. GVSG-mutated FMO2 failed to catalyze disulfide bond formation and lost its protection against ER stress and CM death. Finally, we demonstrated the protective effect of FMO2 in a human induced pluripotent stem cell–derived CM model. Collectively, this study highlights FMO2 as a key modulator of oxidative protein folding in CMs and underscores its therapeutic potential for treating ischemic heart disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou, Zhejiang, China.
- Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, Shanghai Frontiers Science Center of Molecule Intelligent Syntheses, School of Chemistry and Molecular Engineering, East China Nor…
- State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang, China.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Key R & D Projects of Zhejiang Province
Zitieren
APA
Liu, Q., Huang, J., Ding, H., Tao, Y., Nan, J., Xiao, C., Wang, Y., Wu, R., Ni, C., Zhong, Z., Zhu, W., Chen, J., Zhang, C., He, X., Xiong, D., Hu, X., & Wang, J. (2024). Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic activity. Journal of Clinical Investigation, 134(24). https://doi.org/10.1172/jci177077
Vancouver
Liu Q, Huang J, Ding H, Tao Y, Nan J, Xiao C, et al. Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic activity. Journal of Clinical Investigation. 2024;134(24). doi:10.1172/jci177077
BibTeX
@article{Liu2024,
author = {Liu, Qingnian and Huang, Jiniu and Ding, Hao and Tao, Yue and Nan, Jinliang and Xiao, Changchen and Wang, Yingchao and Wu, Rongrong and Ni, Cheng and Zhong, Zhiwei and Zhu, Wei and Chen, Jinghai and Zhang, Chenyun and He, Xiao and Xiong, Danyang and Hu, Xinyang and Wang, Jian'an},
title = {Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic activity},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {24},
doi = {10.1172/jci177077}
}
EUVIMED